Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen, Inc., Karyopharm Therapeutics, Legend Biotech USA, Inc., Oncopeptides, Sanofi Genzyme, Secura Bio, Inc., and Takeda Oncology.

New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variables. This along with the availability of novel therapies and accumulating evidence can make it difficult for clinicians to select appropriate therapy for individual patients. This accredited program discusses patient cases, applicable data, and management strategies in order to facilitate care for patients across the MM disease continuum.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen, Inc., Karyopharm Therapeutics, Legend Biotech USA, Inc., Oncopeptides, Sanofi Genzyme, Secura Bio, Inc., and Takeda Oncology.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Translate patient-specific factors, risk stratification, and treatment history into personalized treatment plans for patients with R/R MM
Assess recent results from pivotal trials on current and emerging therapeutic approaches for the treatment of R/R MM
Implement effective strategies to monitor and mitigate the negative impact of treatment-related toxicities in patients with R/R MM
Apply recent guidelines in parallel with practice-changing evidence on evolving single agent and combination approaches to real-world case scenarios typically encountered in R/R MM management

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Chair

Ajai Chari, MD
Professor of Medicine, Hematology, and Medical Oncology
Icahn School of Medicine at Mount Sinai
Director of Clinical Research, Multiple Myeloma Program
Mount Sinai Health System
New York, NY

Disclosures: Grant/Research Support: Janssen Pharmaceuticals; Celgene Corporation; Novartis; Amgen Inc.; Pharmacyclics; Seattle Genetics, Inc.; Takeda Oncology; Consultant: Janssen Pharmaceuticals; Celgene Corporation; Novartis; Amgen Inc.; Bristol Myers Squibb; Karyopharm Therapeutics; Sanofi Genzyme; Seattle Genetics, Inc.; Oncopeptides, Inc.; Takeda Oncology; Antengene Corp; GlaxoSmithKline; Secura Bio Limited; Shattuck Labs.

Faculty

Sikander Ailawadhi, MD
Professor of Medicine
Lead, International Cancer Center
Division of Hematology/Oncology
Department of Medicine
Mayo Clinic
Jacksonville, FL

Disclosures: Grant/Research Support: Pharmacyclics; Bristol Myers Squibb; GlaxoSmithKline; Amgen Inc.; Janssen Pharmaceuticals; AstraZeneca; Cellectar Biosciences, Inc.; Ascentage Pharma Group; Consultant: BeiGene; Oncopeptides, Inc.; Takeda Oncology; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals; Karyopharm Therapeutics.

Nizar Jacques Bahlis, MD
Associate Professor
Hematology and Bone Marrow Transplantation
Cumming School of Medicine, University of Calgary
Member, Arnie Charbonneau Cancer Institute
Calgary, AB, Canada

Disclosures: Grant/Research Support: Pfizer; Consultant: AbbVie, Bristol Myers Squibb/Celgene, Janssen Pharmaceuticals, Genentech, Karyopharm Therapeutics, Pfizer, Sanofi Genzyme.

Neha S. Korde, MD
Associate Professor
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Neha S. Korde, MD has no relevant financial relationships with ineligible companies.

Cesar Rodriguez Valdes, MD
Associate Professor of Medicine
Hematology and Medical Oncology
Clinical Director, Multiple Myeloma
The Mount Sinai Hospital
New York, NY

Disclosures: Consultant: Amgen Inc.; Janssen Pharmaceuticals; Bristol Myers Squibb; Oncopeptides, Inc.; Karyopharm Therapeutics; Takeda Oncology; Grant/Research Support: Amgen Inc.; Janssen Pharmaceuticals; Bristol Myers Squibb; Oncopeptides, Inc.; Karyopharm Therapeutics; Takeda Oncology.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.